Introduction
The modern approach (ie, long-term oxygen therapy, rehabilitation, and home mechanical ventilation) has contributed to the survival of patients with chronic respiratory diseases, such as COPD. 1 Every day, physicians have to face end-of-life decisions in exacerbations occurring in end-stage patients when endotracheal intubation and/or tracheostomy may be neither appropriate nor accepted (do not intubate and/or do not cannulate status, respectively) due to the high rate of severe complications of invasive mechanical ventilation. 2 The treatment of acute-on-chronic respiratory failure without multiple-organ failure is usually performed in respiratory ICUs (RICUs), which may provide different levels of noninvasive and invasive ventilatory assistance 3 at lower costs compared with ICUs. 4 Moreover, the RICU is a setting where end-of life decisions are made and noninvasive ventilation (NIV) in do-not-intubate and/or do-notcannulate patients is frequently performed. 2 In the literature, there are many reports showing that, in acute hypercapnic exacerbations of COPD, NIV (in addition to medical and oxygen therapy) reduces the need for endotracheal intubation and avoids invasive mechanical ventilation-related complications. [5] [6] [7] In the case of NIV failure, invasive mechanical ventilation or tracheostomy is needed. The main causes of NIV failure are poor patient compliance, difficult management of bronchial secretions, and worsening or lack of improvement in either blood gas values or sensorium. 8 To reduce the rate of treatment failure, different integrated strategies have been successfully implemented during NIV in expert RICU and ICU settings, such as careful pharmacologic sedation to improve a patient's cooperation, 9 early fiberoptic bronchoscopy, and/or high-frequency chest wall compressions (HFCWC) to promptly remove the excessive burden of secretion in COPD subjects with respiratory muscle fatigue and ineffective cough. 10, 11 Extracorporeal CO 2 removal, which developed from the traditional extracorporeal membrane oxygenation, 12, 13 has been recently proposed as an alternative or an integrated therapeutic option in patients with acute hypercapnic acidotic respiratory failure who are non-responders to an NIV trial. 14, 15 Although extracorporeal membrane oxygenation is a total extracorporeal support that is able to oxygenate severely hypoxemic patients and remove up to 50% of the total body CO 2 production, extracorporeal CO 2 removal works as a partial extracorporeal support capable of removing lower amounts of CO 2 without substantial effects on oxygenation. Less invasive than extracorporeal membrane oxygenation (lower blood flows, smaller diameter cannulation, lower doses of heparin), extracorporeal CO 2 removal is associated with fewer severe complications. 13, 16, 17 There are 2 different extracorporeal CO 2 removal approaches: (1) arteriovenous extracorporeal CO 2 removal works as a pumpless bypass between a femoral arterial and contralateral femoral vein; and (2) venovenous extracorporeal CO 2 removal is a simple, pump-driven, low blood flow, venovenous system composed of a hemofilter and an oxygenator. Serious vascular complications have been reported in 24% of patients treated with the arteriovenous pumpless device, which requires arterial cannulation with large catheters. 18 In this paper, we report a case of hypercapnic acute-onchronic respiratory failure occurring in a patient with endstage COPD who declined endotracheal intubation and was treated with integrated and sequential use of NIV together with fiberoptic bronchoscopy, HFCWC, and venovenous extracorporeal CO 2 removal.
Case Summary
An 82-y-old female smoker with very severe COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage IV) and anxiety on long-term home oxygen therapy was admitted to our RICU for dyspnea, fever, cough with yellow sputum, and a severely altered state of consciousness (Kelly score 4). 19 Chest x-ray showed a left lower lobe consolidation with an ipsilateral mild pleural effusion (Fig. 1 ). Blood chemistry tests revealed leukocytosis (15,400 white blood cells/L), and arterial blood gas analysis under oxygen therapy (F IO 2 ϭ 0.5) showed severe hypercapnia and moderate respiratory acidosis with severe hypoxemia (pH 7.25, P aO 2 ϭ 73 mm Hg, P aCO 2 ϭ 80 mm Hg, HCO 3 Ϫ ϭ 34 mmol/L, and S aO 2 ϭ 92%). The patient was treated with intravenous pharmacologic therapy (levofloxacin 500 mg once daily, piperacillin/tazobactam 4.5 g three times daily, methylprednisolone 40 mg once daily), subcutaneous enoxaparin (4,000 IU), aggressive chest physiotherapy, NIV via a total-face mask (PerforMax, large, Philips Respironics, Murrysville, Pennsylvania) in a pressure-assisted control mode (pressure support ϭ 17 cm H 2 O, PEEP ϭ 6 cm H 2 O, breathing frequency ϭ 16 breaths/min, F IO 2 ϭ 0.4), and inhaled bronchodilators and steroids during ventilation (salmeterol 100 g, fluticasone 1,000 g twice daily via a metereddose inhaler with a spacer). Despite an initial improvement of gas exchanges and sensorium (Kelly score 3) after 2 h of treatment, neurological and respiratory conditions progressively worsened during the following 2 d of almost continued NIV (Table 1) , with accumulation of a large amount of bronchial secretions associated with a depressed and ineffective cough reflex.
On the third and fourth days after hospitalization, 2 fiberoptic bronchoscopy procedures with bronchoalveolar lavage during NIV were performed according to a standardized protocol 10 to remove the abundant bronchial secretions. A cap of thick mucus in the lower left lobar bronchus was aspirated, resulting in a rapid improvement of P aO 2 /F IO 2 and in radiographic signs of atelectasis (Table  1 and Fig. 2 ). Bronchoalveolar lavage fluid analysis was negative for a large panel of microbiological agents.
Respiratory physiotherapy was implemented using the HFCWC system dispensed by the Vest (Hill-Rom, St Paul, Minnesota) at a frequency of 7 Hz, a rise of 5, and a duration of 5 min three times/d during the short periods of NIV disconnection. On the fifth day, after 92 h of NIV, the patient's conditions deteriorated again, with a severe increase in hypercapnia, a contextual drop in pH, and depression of the sensorium status. Because of the poor respiratory conditions of the patient, with 3 hospitalizations for acute-on-chronic respiratory failure in the previous 6 months, endotracheal intubation and tracheostomy were considered inappropriate by the physicians of the pulmonary unit who had cared for her for several years. The potential complications of invasive mechanical ventilation in an advanced stage of COPD had been clearly explained during previous follow-up visits, and the patient had declared that she would not accept endotracheal intubation, tracheostomy, or home invasive mechanical ventilation. On admission to the RICU, endotracheal intubation had been declined by relatives. After obtaining the family's consent, NIV was withdrawn, and a session of extracorporeal CO 2 removal (Decap, Hemodec, Salerno, Italy) was attempted. Briefly, a 14 French femoral catheter was introduced, and heparin infusion was started and titrated to maintain the activated partial thromboplastin ratio at 1.5 times the basal value. After 1 h of treatment, the P aCO 2 dropped, with a further reduction in hypercapnia after 8 h. During extracorporeal CO 2 removal, dyspnea, breathing frequency, and sensorium also improved.
During extracorporeal CO 2 removal, the patient remained hemodynamically stable, but after 8 h of treatment, we decided to stop the treatment and to remove the vascular catheter because of hematuria, anemia, and inguinal subfascial hematoma. Due to the lack of a full recovery of sensorium and to the persistent severe hypoxemia with respiratory alkalosis after the extracorporeal CO 2 removal treatment, on the sixth day, intermittent NIV was then resumed with integrated sessions of HFCWC. There was a progressive improvement in clinical conditions, radiological findings, and gas exchange. Ventilation was stopped at 20 d after admission to the RICU.
The patient was discharged after 24 d of hospitalization under home oxygen therapy (flow of 1 L/min) and fair gas INTEGRATED THERAPEUTIC STRATEGY DURING NIV exchange (pH 7.38, P aO 2 ϭ 64 mm Hg, P aCO 2 ϭ 59 mm Hg, HCO 3 Ϫ ϭ 34 mmol/L, S aO 2 ϭ 93%).
Discussion
In this case report, we described the integrated strategies that may be used to manage NIV failure in patients with end-stage COPD in acute-on-chronic respiratory failure when endotracheal intubation and invasive mechanical ventilation are neither accepted by patients and their relatives nor considered appropriate by the treating physicians (ie, do not intubate and do not cannulate). Even if some of the reported techniques (fiberoptic bronchoscopy, HFCWC) are not new and are largely applied in the intensive care setting, in this case report we highlight the feasibility of an integrated strategy in the specific scenario of do-not-intubate/do-not-cannulate status occurring in patients in advanced stages of chronic respiratory diseases who have failed NIV. We note that even if short-term extracorporeal CO 2 removal treatment seems to be effective in improving hypercapnia within the sequential combined NIV strategy, this invasive CO 2 removal technique may induce serious adverse effects in patients who have refused endotracheal intubation and invasive mechanical ventilation for their potential life-threatening complications.
The main predictors of NIV failure are: worsening or lack of improvement in pH and breathing frequency after 2 h of treatment, higher severity scores of acute illness at admission, low compliance with treatment, and presence of ARDS or pneumonia. 8 Another important cause of ventilation failure is the accumulation of dense secretions due to weak cough. 20, 21 Antonelli et al 22 reported NIV failure in 30% of their patients. In their population, the need for rescue endotracheal intubation and invasive mechanical ventilation was linked mainly to the presence of ARDS or community-acquired pneumonia and less frequently to heart failure or lung contusion. However, in the case of NIV failure, escalating therapy involving invasive mechanical ventilation and eventually tracheostomy may be questionable in patients with end-stage acute-on-chronic respiratory failure. According to a European survey performed in RICUs, 21% of patients expressed their end-of-life decisions, and most of them refused endotracheal intubation, indicating the ceiling NIV as the most acceptable treatment. 2 Our patient should have received endotracheal intubation and invasive mechanical ventilation because of the progressive worsening of acidosis during NIV and the presence of accumulated secretions associated with a severely Previous studies demonstrated that patients with acute-onchronic respiratory failure and bronchial hypersecretion of different etiology showed improvement in P aO 2 and P aCO 2 when NIV was provided with HFCWC. 23, 24 However, a systematic review has not demonstrated the usefulness of HFCWC in improving the clinical outcomes of hospitalized patients with COPD exacerbation compared with the usual medical care; consequently, the role of this technique in these patients still remains controversial. 25 Given the persistent respiratory acidosis and altered sensorium during NIV despite the improvement in P aO 2 after fiberoptic bronchoscopy, we decided to proceed with extracorporeal CO 2 removal, which resulted in arterial blood gas improvement after a few hours of treatment. Recently published papers showed that this non-ventilatory technique was able to correct severe hypercapnia and to reduce the need for endotracheal intubation in COPD exacerbations. 14, 15 Despite these preliminary promising findings, the large-scale application of extracorporeal CO 2 removal for the treatment of hypercapnic patients with COPD needs more research; specifically, we still do not know when and how to use this CO 2 removal technique during an episode of hypercapnic acute-on-chronic respiratory failure in patients with COPD. Moreover, this technique is not without risk. According to National Institute for Health and Care Excellence (NICE) guidelines for extracorporeal membrane treatments, the main extracorporeal CO 2 removal-related adverse effects are ischemic complications with compartment syndrome (4%), thrombosis (2-5%), and bleeding (4%). 16 In our case, we had to stop the treatment because the patient developed a subfascial inguinal hematoma above the venous catheter insertion area with anemia. This might have raised ethical issues in a patient who had expressed the wish of avoiding invasive procedures. However, the decision clearly referred to the application of an artificial airway with all the potential implications (recurrent infections, ventilator dependence, difficulty in speaking and eating). We did not have a chance to discuss with the patient either the use of extracorporeal CO 2 removal as a possible alternative for endotracheal intubation and invasive mechanical ventilation or the potential serious complications that the CO 2 removal technique may induce. It was possible to discuss only with the relatives the balance between benefits and risks of extracorporeal CO 2 removal and the ethical dilemma of using this procedure in a donot-intubate/do-not-cannulate patient.
In agreement with previous reports, 14, 15, 26 gas exchange improvement continued even after cessation of extracorporeal CO 2 removal. The persistence of clinical-physiologic improvement after a very short time of extracorporeal CO 2 removal is surprising, and the underlying pathophysiologic mechanisms are still unknown. In our opinion, the reported improvement was linked not just to extracorporeal CO 2 removal but also to the combined strategy that included NIV, fiberoptic bronchoscopy, physiotherapy, and pharmacologic treatment. CO 2 removal alone may be not sufficient to achieve a greater oxygenation level. Due to its technical features (ie, low flow, small catheter diameter), extracorporeal CO 2 removal is not intended to improve oxygenation, and, not surprisingly, we observed a drop in P aO 2 /F IO 2 during treatment. In contrast, extracorporeal CO 2 removal was effective in reducing acidosis and improving sensorium and cough reflex. The combined effect of hypoxemia and respiratory alkalosis may have detrimental effects on oxygen delivery in critical respiratory patients; this is why we decided in our case to resume NIV with HFCWC sessions during the ventilationfree time.
Finally, we should underscore the importance of the environment where we applied this NIV-based integrated strategy. Our patient was managed in an RICU 3 with a high level of assistance (nurse-to-patient ratio of 1/3, one respiratory therapist per shift), long-term experience with NIV and fiberoptic bronchoscopy techniques, and continuous multiparametric monitoring systems.
In conclusion, we report the feasibility and usefulness of combination therapy (fiberoptic bronchoscopy, HFCWC, and CO 2 removal) with NIV performed together or in serial steps in the treatment of selected cases of NIV failure if endotracheal intubation is refused and/or considered inappropriate (Fig. 3) . However, important limitations of this integrated approach should be emphasized. First, we do not know if the result obtained with this single case treated in a single center could be replicated in other similar patients admitted in other units. Second, we do not know if the same outcome might have occurred if some of the approaches had been omitted or perhaps if others had been added. Third, the costs of this integrated approach were not calculated but are not negligible. Fourth, the course of extracorporeal membrane oxygenation was so short that it is difficult to know whether this made any difference in the outcome. Finally, ethical issues should be considered regarding the risk of potentially serious complications correlated with the use of extracorporeal CO 2 removal in the setting of do-not-intubate/do-not-cannulate patients who refuse invasive procedures.
Teaching Points
• Sequential use of different therapeutic respiratory procedures (ie, fiberoptic bronchoscopy, HFCWC) is feasible to manage NIV failure in the specific scenario of end-stage patients with severe acute-on-chronic respiratory failure when endotracheal intubation is either refused or considered inappropriate. However, its effectiveness and safety have to be demonstrated in larger and multi-center studies.
• Even though fiberoptic bronchoscopy and HFCWC may be effective in acute hypercapnic patients with COPD who are failing NIV due to accumulation of a large amount of bronchial secretions, the role of these techniques in COPD exacerbations is still controversial.
• Even though a short treatment of extracorporeal CO 2 removal may be effective in quickly and persistently removing excess CO 2 in severely hypercapnic, acutely decompensated patients with COPD who fail with NIV assistance, the widespread use of this approach, especially in do-not-intubate patients, cannot be recommended due to the potential serious complications and the lack of robust proven clinical evidence.
• The type of environment (ie, ICU and RICU) and the expertise of the respiratory team are essential to safety in applying complementary and integrated respiratory treatments to patients with acute-on-chronic respiratory failure who do not respond successfully to NIV. Fig. 3 . Proposal of a flow chart depicting the potential integrated respiratory therapies in adjunct to noninvasive ventilation (NIV) in the case of risk of failure in patients with acute-on-chronic respiratory failure (ACRF) and do-not-intubate (DNI) status. HE ϭ hypercapnic encephalopathy; FOB ϭ fiberoptic bronchoscope; HFCWC ϭ highfrequency chest wall compression; ECCO 2 R ϭ extracorporeal CO 2 removal.
